ClinicalTrials.gg
RecruitingNCT07462910DEFINE-PFAUpdated Jun 10, 2026

Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction Related to Electroporation

An interventional study of Dynamic fluoroscopy in Atrial Fibrillation, sponsored by French Cardiology Society. Recruiting at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by French Cardiology Society · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Planned enrollment
96th of 193
250 · median 250
Started
2026
with 14 others
No phase
117 of 317
32 open now
Primary completion
2027-05
later than 41 of 86 live
Registered
305th of 317
by date

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 96th largest by planned enrollment of the 193 interventional ones that give a count, is one of 15 that started in 2026, is one of 117 with no phase, reaches primary completion later than 41 of the 86 other live ones, and was the 305th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

Pulsed Field Ablation (PFA) represents a recent advance in the treatment of atrial fibrillation (AF), with a safety profile potentially superior to traditional thermal techniques, such as radiofrequency or cryoablation. Its mechanism of action allows tissue selectivity which in theory limits damage to extracardiac structures. However, several cases of right diaphragmatic paralysis have been reported in the literature after PFA, particularly during applications on the right pulmonary veins, near the right phrenic nerve. The available data are from studies without specific diaphragmatic monitoring. The diagnosis of diaphragmatic paralysis is most often based on chest X-ray, a static examination of limited sensitivity, especially for the detection of incomplete paralysis. To date, no prospective multicentre study has evaluated the incidence of diaphragmatic paralysis after PFA with systematic dynamic imaging, such as fluoroscopy, considered the gold standard for the diagnosis of unilateral paralysis.

Read the detailed description

The current study, DEFINE-PFA, aims to include 250 patients spread over 9 centres (France, New-Zealand and Canada). Each patient will benefit from dynamic fluoroscopy before and after the procedure. A new fluoroscopy will be performed at 3 months in patients with a significant reduction (>15%) in postoperative diaphragmatic amplitude.

The primary endpoint is based on the appearance of post-procedure inter-hemi diaphragmatic asymmetry, rather than a simple decrease in craniocaudal amplitude compared to the reference fluoroscopy. Indeed, the absolute diaphragmatic amplitude is highly dependent on the examination conditions, in particular the degree of cooperation of the patient and the intensity of forced inspiration, making inter-examination comparisons unreliable. Conversely, the simultaneous comparison of the two hemidiaphragms during the same inspiratory cycle makes it possible to attenuate these biases by using the contralateral hemidiaphragm as a stable internal reference. Pre-procedure fluoroscopy is nevertheless systematically performed in order to check the absence of basic asymmetry.

The threshold of 15% inter-hemi diaphragmatic asymmetry was empirically retained, in the absence of a cut-off validated in the literature for dynamic fluoroscopy. In diaphragmatic ultrasound, asymmetry is generally considered significant for differences in amplitude > 20% between the two hemi domes, but these measurements are performed successively, which makes them sensitive to variations between respiratory cycles. Conversely, fluoroscopy allows simultaneous observation of the two hemidiaphragms during the same respiratory cycle, offering a more reliable comparison. This threshold aims to detect significant asymmetry while minimizing false positives related to physiological variability.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Pulsed Field Ablation
  • Fluoroscopy
  • Diaphragmatic monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years or older at the time of signing the consent (age≥ 18).
  • Diagnosis of paroxysmal or persistent atrial fibrillation, documented in any type of means: , Holter, invasive monitoring (memories of an implantable device) or not (connected objects).
  • Indication for ablation decided as part of routine care, according to the recommendations of learned societies.
  • First, ablation procedure (including pulmonary vein isolation) planned with the use of a commercially available Pulsed Field Ablation catheter.
  • Possibility of performing a fluoroscopic diaphragmatic evaluation before and after the operation (before discharge from the hospital).
  • Free, informed and signed consent by the patient before any data collection

Exclusion criteria

Exclusion Criteria:

  • Known history of diaphragmatic paralysis (right or bilateral) or pre-existing clinical suspicion.
  • History of atrial fibrillation ablation.
  • History of neuromuscular disease.
  • History of major thoracic surgery or chronic pulmonary pathology that may impair diaphragmatic kinetics.
  • Evidence of diaphragmatic paralysis on the pre-procedure fluoroscopy loop, defined as:

    • Cranio-caudal excursion amplitude ≤35 mm on both hemidiaphragms, Or
    • An asymmetry in contraction amplitude ≥15% between the two sides.
  • Inability to perform a post-procedure follow-up fluoroscopy (logistical limitation, patient refusal, to irradiation).
  • Pregnancy or breastfeeding in progress.
  • Concurrent participation in another interventional study that may interfere with the objectives of this research.
  • Major impairment in cognitive function or inability to understand the objectives of the study or sign a valid consent.
  • Individuals deprived of liberty by judicial or administrative decision.
  • Adults subject to a legal protection measure (guardianship, curatorship, or judicial protection/safeguard of justice).
  • Individuals unable to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Intervention

    Systematic observation of an additional examination (dynamic fluoroscopy) performed before and after a Pulsed Field Ablation procedure, as part of the standard management of atrial fibrillation.

    Procedure: Dynamic fluoroscopy

Interventions

  • ProcedureDynamic fluoroscopy

    Fluoroscopic loop recording or continuous digital scopy of the thoracic window, over at least one complete breathing cycle at maximum amplitude.

06

What researchers measure

Primary outcomes

  1. Diaphragmatic paralysis

    Post-procedural occurrence of diaphragmatic contraction asymmetry, defined as a ≥15% reduction in the cranio-caudal amplitude of a hemi-diaphragm, relative to the contralateral side, measured by dynamic fluoroscopy during a forced breathing cycle, and absent on pre-procedure fluoroscopy.

    Time frame: Day1: Before the Pulsed Field Ablation and after the Pulsed Field Ablation (at hospital discharge between 2 and 30 hours after ablation, according to a rigorously standardized protocol in all participating centres)

Secondary outcomes

  1. Rate of complete or partial recovery of diaphragmatic function at 3 months.

    For patient with diaphragmatic paralysis observed at inclusion visit, diaphragmatic contraction asymmetry evaluation will be redo after 3 months.

    Time frame: At 3 months

  2. Evaluation of symptoms associated with diaphragmatic paralysis

    Presence / absence of symptoms : dyspnea, discomfort on inspiration, decreased physical capacity, sleep disturbances.

    Time frame: Day 1, at 3 months

  3. Evaluation of the efficiency of the procedure

    Comparison, between patients who experienced diaphragmatic paralysis after ablation and those who did not, of the duration of the procedure (in minutes), the duration of the endoscopy (in minutes), the total number of applications and the type of catheter used.

    Time frame: Day1

07

Study locations

1 of 9 sites recruiting
  • Montreal Heart Institute
    Montreal, QC H1T 1C8, Canada
    Not yet recruiting
    • Laurent MACLE, MD · Contact
  • CHRU de Tours - Hôpital Trousseau
    Chambray-lès-Tours, 37170, France
    Not yet recruiting
    • Arnaud BISSON, MD · Contact
  • CHU de Lyon - Hôpital Croix-Rousse
    Lyon, 69004, France
    Not yet recruiting
    • Sami FAREH, MD · Contact
  • Centre Hospitalier de Pau - Hôpital François Mitterrand
    Pau, 64046, France
    Recruiting
    • Hugues BADER, MD · Contact
  • CHU de Bordeaux - Hôpital Haut-Lévêque
    Pessac, 33604, France
    Not yet recruiting
    • Romain TIXIER, MD · Contact
  • Centre Cardiologique du Nord
    Saint-Denis, 93200, France
    Not yet recruiting
    • William ESCANDE, MD · Contact
  • Institut Cardiovasculaire de Strasbourg - Clinique Rhéna
    Strasbourg, 67000, France
    Not yet recruiting
    • Babé BAKOUBOULA, MD · Contact
  • Clinique Pasteur
    Toulouse, 31300, France
    Not yet recruiting
    • Serge BOVEDA, MD · Contact
  • Auckland City Hospital
    Auckland, 1023, New Zealand
    Not yet recruiting
    • Nigel LEVER, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 11 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 10, 2026
StartActual
Jun 2, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462910
Lead sponsor
French Cardiology Society
Collaborators
Circle Safe, IHU Lyric, ADIMEP
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Jun 2, 2026
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Tessa BERGOT, MSc
Contact
tessa.bergot@sfcardio.fr
+33144907033
Romain TIXIER, MD
study chair · University Hospital, Bordeaux
Frédéric FRANCESCHI, MD
study director · CHU Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion